Dr. Ramesh K. Ramanathan is a board-certified medical oncologist, he joined Ironwood Physicians as Medical Director of Clinical Research in October 2023.
Dr. Ramanathan, previously lived in Phoenix prior joining the pharmaceutical Industry as Executive Director, Global Scientific Affairs, Merck Research Labs, Rahway, NJ, USA and Vice President, Zielbio, Charlottsville, VA.
Dr. Ramanathan served on the faculty of Mayo Clinic, Phoenix, AZ (2014-2018) and held appointments as Professor of Medicine at the Mayo Medical school with a joint appointment at the Translational Genomics Research Institute (TGEN), Phoenix, AZ. Prior to joining Mayo Clinic, he served as the medical director of the Virginia G. Piper Cancer Ctr- Clinical Trials Program, Scottsdale, AZ from 2007-2014 and at the University of Pittsburgh Cancer Institute from 1996-2007.
Dr. Ramanathan is a recognized expert for GI cancers and has research interests in new drug development. In the last 25 years, Dr. Ramanathan has been involved in the development of several new drugs (PARP, PI3K, hedgehog inhibitors, liposomal formulations etc), participated in numerous first in human agent studies and had a pivotal role in the development and approval of oxaliplatin for colon cancer and nab-paclitaxel for pancreatic cancer. He has published more than 200 papers in peer reviewed journals, as well as numerous book chapters. Dr Ramanathan has served on national professional committees and been an invited speaker at national and international meetings. Dr. Ramanathan is an Editorial Board member for Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, Gastrointestinal Cancer Research and is an ad hoc reviewer for several high impact journals.
At Ironwood Physicians, Dr. Ramanathan will leverage his extensive experience from both academia and industry to expand the clinical trials program with innovative new agents. He also will have an active practice consulting on GI cancer patients. His other interests are cycling, tennis, chess and travelling.
Phase II trial of Dacarbazine (DTIC) in advanced pancreatic islet cell carcinomas. Study of the Eastern Cooperative Oncology Group (E6282). Ann Oncol 12.1139-43.2001.
Ramanathan RK, Cnaan C, Hahn RG, Carbone PP, Haller DG.
A Randomized Trial of Influenza Vaccine with GM-CSF or Placebo in Cancer Patients. J Clin Oncol.20: 4313-4318; 2002.
Safety and Toxicity Analysis of Oxaliplatin combined with 5-Fluorouracil or as a Single Agent in more than 5000 Patients with Previously Treated Advanced Colorectal Cancer.
J Clin Oncol: 21, 2904-2911; 2003
Ramanathan RK, Clark J, Kemeny N, Lenz H-J, Gococo K, Haller D, Mitchell E, Kardinal C
A randomized controlled trial of fluorouracil plus leucovorin irinotecan and oxaliplatin combinations in patients with previously untreated colorectal cancer. J Clin Oncol 22; 22-30; 2004
Goldberg RM, Sergeant DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR.
Phase I Pharmacokinetic-Pharmacodynamic Study o17AAG,(NSC 330507), A Novel Inhibitor of Heat Shock Protein 90, in Patients With Refractory Advanced Cancers. Clin Cancer Res.11: 3385-91:2005.
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with
unresectable or metastatic pancreatic cancer. Ann Oncol. 16:1639-45, 2005.
Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL.
Phase I and Pharmacokinetic Study of the Novel Redox-Active Agent, Motexafin Gadolinium, with Concurrent Radiation Therapy in Patients with Locally Advanced Pancreatic or Biliary Cancers. Cancer Chemother Pharmacol.57:465-74; 2006.
RK Ramanathan, M Fakih, S Mani, M Deutsch, RP. Perez, MA. Ritter, JL. Eiseman2,, S.P Ivy, DL Trump, CP. Belani, RA. Parise, DM. Potter and MJ. Egorin.
Phase I and Pharmacodynamic Study of 17AAG, (NSC 330507), Administered on a Twice-a- Week Schedule, in Adult Patients with Refractory Advanced Cancers. Clin Can Res 13; 1769- 1774: 2007.
Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS. Percy Ivy S, Potter DM, Chatta G, Zuhowski EG, Stoller RG, Naret C, Guo J, Belani CP.
A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients with Advanced Solid Tumors. Clin Can Res 13: 2109-2114: 2007 Ramanathan RK, Kirkpatrick DL, Belani CP, Friedland D, Green SB, Chow SSH, Cordova CA, Stratton SP, Sharlow ER, Baker A and Dragovich T.
A Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction. A Study by the National Cancer Institute-Organ Dysfunction Working Group. J Clin Oncol; 26:563-9: 2008
Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA, Mulkerin D Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP, Hayes MJ, Peng B, Ivy SP.
A Phase II, Four Arm Randomized, Multicenter Trial of Oxaliplatin Combined With Varying Schedules of 5-Fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. Clin Colorectal Can. 7: 134-139: 2008.
Ramanathan RK, Bjarnason GA, Bernard SA, Desimone P, Braich T ,Evers JP, Hrushesky WJ, Jolivet J.
A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Therapy; 6:955-964: 2008.
Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients with Advanced Malignancies. Clin Cancer Res;15:1466-72; 2009.
A Phase II Study of Lapatinib in Patients with Advanced Biliary Tree and Hepatocellular Cancer. Can Chemo Pharmacol.64:777-83: 2009.
Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: A pooled analysis of three phase III studies. Ann Oncol.21:754- 8: 2010
Phase I, Pharmacokinetic, and Pharmacodynamic Study o17DMAG, (NSC 707545), an Inhibitor of Heat Shock Protein 90, in Patients With Advanced Solid Tumors. J Clin Oncol.28:1520-6: 2010
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial. J Clin Oncol. 29:4548-54: 2011
R L. Korn, N Desai, V.Trieu, JL. Iglesias, H Zhang, P Soon-Shiong, T. Shi,
N.V. Rajeshkumar, A. Maitra, and M. Hidalgo.
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine.. N Engl J Med.369 :1691-703: 2013.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF.
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. Br J Cancer. 111:272-80: 2014.
Patnaik A, Weiss GJ, Papadopoulos KP, Hofmeister CC, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo FC, Cotreau MM, Ramanathan RK.
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. Eur J Cancer. 50:2897-904: 2014.
Infante JR, Weiss GJ, Jones S, Tibes R, Bauer TM, Bendell JC, Hinson JM Jr, Von Hoff DD, Burris HA 3rd, Orlemans EO, Ramanathan RK.
A Phase II Study of MK-2206, an Allosteric Inhibitor of AKT as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer, a SWOG Cooperative Group Trial (S1005). Cancer. 2015;121:2193-7
Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TC, Lim HJ, Hezel AF, Vaccaro GM, Blanke CD.
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med.373:428-37: 2015.
Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK etal (+ 18 authors)
Safety, Pharmacokinetics and Pharmacodynamics of a Humanized anti-Semaphorin 4D
Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. Clin Cancer Res. 15;22:827-36: 2016.
Patnaik A, Weiss GJ, Leonard JE, Rasco D, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK.
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. Ann Oncol. 27:648-53: 2016.
Ramanathan RK, Goldstein D, Korn RL, Arena F, Moore M, Siena S, Teixeira L, Tabernero J, Van Laethem JL, Liu H, McGovern D, Lu B, Von Hoff DD.
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non- Hodgkin’s lymphomas. Ann Oncol. 27:1928-40: 2016
Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvresse I, Ramanathan RK.
Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline. Ann Oncol. 27:1647-8; 2016. Ramanathan RK, Korn RL, Chiorean EG, Liu H, Von Hoff DD.
Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib
in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
Cancer Discov. 7:620-629. 2017
de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.
Correlation Between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients With Advanced Solid Tumors: A Pilot Study. Clin Cancer Res. 23:3638-3648: 2017
Ramanathan RK, Korn R, Raghunand N, Sachdev JC, Newbold RG, Jameson G, Fetterly GJ, Prey J, Klinz SG, Kim J, Cain J, Hendriks BS, Drummond DC, Bayever E, Fitzgerald JB.
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer. 2018;118:153-161I
Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK.
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. J Gastro Intest Onc. 2018, 8: 925-93. Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack B, Maitra M, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barret MT.
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313. J Clin Oncol. 2019;37:1062-1069
Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar J, Chiorean EG, Shields AF, Behl D, Mehan PT, Gaur R, Seery T, Guthrie KA, Hochster HS.
Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature. 2019;567 :249-252
Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham K, Gladney WL, Hua X, Black TA, Chien AL, Majmundar KS, Thompson JC, Yee SS, O’Hara MH,
Aggarwal C, Xin D, Shaked A, Gao M, Liu D, Borad MJ, Ramanathan RK, Carpenter EL, Ji A, de Beer MC, de Beer FC, Webb NR, Beatty GL
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2020;19:1210-1217 Strickler JH, LoRusso P, Salgia R, Kang YK, Yen CJ, Lin CC, Ansell P, Motwani M, Wong S, Yue H, Wang L, Reilly E, Afar D, Naumovski L, Ramanathan RK.
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Target Oncol. 2020;15:163-174 Ramanathan RK, Von Hoff DD, Eskens F, Blumenschein G Jr, Richards D, Genvresse I, Reschke S, Granvil C, Skubala A, Peña C, Mross K.
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. Ando K, Ozonoff A, Lee SY, Voisine M, Parker JT, Nakanishi R, Nishimura S, Yang J, Grace Z, Tran B, Diefenbach TJ, Maehara Y, Yasui H, Irino T, Salgia R, Terashima M, Gibbs P, Ramanathan RK, Oki E, Mori M, Kulke M, Hartshorn K, Bharti A. Clin Colorectal Cancer. 2021. 20(2):129-1
Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of dilpacimab in patients with advanced solid tumors.
Gordon MS, Nemunaitis J, Barve M, Wainberg ZA, Hamilton EP, Ramanathan RK, Sledge GW, Yue H, Morgan-Lappe SE, Blaney M, Kasichayanula S, Motwani M, Wang L, Naumovski L, Strickler JH. Mol Cancer Ther. 2021 Jul 26: Online ahead of print.
No videos found.
685 S. Dobson Rd.
Chandler, AZ 85224
Hours:
Monday- Friday
8am-5pm
8880 E. Desert Cove Ave.
Scottsdale, AZ 85260
Hours:
Monday-Friday
8am-5pm
